Issue 3 2017

2 LATIN AMERICA NEWS / Issue 3 2017 Editor’s Note , Welcome to this informative 3rd edition of Latin America News. In recent news, leading biopharmaceutical company in Latin America, Grupo Biotoscana has announced the acquisition of Laboratorio DOSA, a specialty pharmaceutical manufacturer based in Argentina. The transaction continues to advance GBT’s strategic agenda and expands GBT’s scope into the promising area of severe lung diseases. Elsewhere in this issue, we discover how AudioTrade DSP integrates with Triton Digital’s a2x® to provide LATAM Buyers with access to premium digital audio advertising inventory. The integration enables buyers that use the AudioTrade platform to expand their reach by adding the premium, global audio inventory within a2x to their programmatic buys. Lastly, leader in providing highly reliable, fully managed, remote communication and IT solutions, and SES, the world-leading satellite operator, Speedcast has announced an agreement to provide several hundreds of Mbps of connectivity into Peru. This is the first agreement between the companies in Latin America to provide Medium Earth Orbit (MEO) capacity, with high throughput capabilities and low latency. Here at Latin America News, we truly hope you enjoy reading this insightful issue and look forward to hearing from you soon. Jessica Daykin, Editor Phone: +44 (0) 203 725 6842 Email: jessica.dayki [email protected] Website: www.latinamerica-news.com AI Global Media, Ltd. (AI) takes reasonable measures to ensure the quality of the information on this web site. However, AI will not assume any legal liability or responsibility for the accuracy, correctness or completeness of any information that is available through this web site. If errors are brought to our attention, we will try to correct them. The information available through the website and our partner publications is for your general information and use and is not intended to address any particular finance or investment requirements. In particular, the information does not constitute any form of advice or recommendation by us or any of our partner publications and is not intended to be relied upon by users in making or refraining from making any investment or financial decisions. Appropriate independent advice should be obtained before making any such decision. Any arrangement made between you and any third party named in the site is at your sole risk and responsibility.